title: [Dynamics of lipid peroxidation and antioxidant defense in response to dalteparin therapy in acute coronary syndrome].
abstract: The aim of the study was examination of lipid peroxidation (LPO) and antioxidant system (AOS) in patients with acute coronary syndrome (ACS); evaluation of the effect of dalteparin therapy on LPO and ACS. Fifty one patients (mean age 57.5 +/- 1.5 years) were randomized into two groups: group 1 (n = 31) received low-molecular heparin dalteparin, group 2 (n = 17) was given non-fractionated heparin. The course of the anticoagulant therapy lasted 8 days. LPO and antioxidant defense in plasm and blood red cells were investigated on day 1 and 9. ACS patients appeared to have elevated LPO products production both in plasm and blood red cells, low plasm antioxidant activity (AOA). Dalteparin therapy lowered content of malonic dialdehyde (MD) in red cells and plasm, AOA enhanced. Heparin activity was lower: MDA in plasm decreased in a lesser degree while MDA in red cells continued to rise in lowering AOA in plasm and inhibition of catalase.
authors.forename: N I
authors.initials: NI
authors.lastname: Tarasov
authors.forename: N V
authors.initials: NV
authors.lastname: Terent'eva
authors.forename: N L
authors.initials: NL
authors.lastname: Vorontsova
authors.forename: L S
authors.initials: LS
authors.lastname: Barbarash
mesh_terms: D000208:Acute Disease; D000975:Antioxidants / Q000378:metabolism*; D003327:Coronary Disease / Q000188:drug therapy / Q000378:metabolism / Q000503:physiopathology; D017985:Dalteparin / Q000627:therapeutic use*; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006801:Humans; D015227:Lipid Peroxidation / Q000502:physiology*; D008297:Male; D008875:Middle Aged
chemical_list: D000975:Antioxidants; D005343:Fibrinolytic Agents; D017985:Dalteparin